Latest Regulatory News

Galilee Energy Limited has been reinstated to trading on the ASX following the announcement of a significant capital raising and acquisition, signaling a pivotal moment for the energy explorer.

Galilee Energy has secured an option to acquire the Zydeco Gas Project in Louisiana, marking a strategic expansion into the US market, supported by a A$6.5 million capital raise to accelerate development.

OM Holdings has cleared major regulatory hurdles in the $101 million sale of its 26% stake in Ntsimbintle Mining, moving closer to closing the deal in early 2026.

OM Holdings has secured key regulatory and shareholder approvals for the sale of its 26% interest in Ntsimbintle Mining, moving the $101 million transaction closer to completion early next year.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.

Brightstar Resources has completed its acquisition of Aurumin Limited, converting Aurumin shares and options into Brightstar securities and prompting Aurumin’s imminent delisting from the ASX.

FireFly Metals has successfully raised over C$30 million through a Canadian bought deal and approximately A$106.5 million via an Australian equity raise to fund key development and exploration at its Green Bay Copper-Gold Project in Newfoundland.

Jameson Resources has locked in a $3 million capital raise from strategic investor King George Investments to advance its Crown Mountain coal project in British Columbia. The placement, priced at a 16.7% discount, underscores growing confidence in the project’s regulatory progress and market potential.

NexGen Energy has reported its highest-grade uranium assay to date from the Patterson Corridor East at its Rook I Project, revealing exceptional mineralization that could redefine the project's potential.

Vitasora Health has secured AU$3.56 million from a cornerstone investor, issuing over 118 million shares, while confirming compliance with key regulatory disclosure obligations.

L1 Global Long Short Fund Limited is raising up to AUD 415 million through a pro-rata entitlement offer to support its transition to L1 Capital's Global Long Short Strategy, following a management change and portfolio overhaul.

Immutep Limited reveals promising Phase II results from its AIPAC-003 trial, establishing 30 mg as the optimal biological dose of eftilagimod alfa combined with paclitaxel in metastatic breast cancer patients.